Personalized HIV dosing: genetic and drug monitoring trial aims to reduce side effects

NCT ID NCT03385473

Completed Knowledge-focused Sponsor: Hospital Italiano de Buenos Aires Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This completed study tested whether using genetic information and measuring drug levels in the blood can help doctors choose the right dose of HIV medications (efavirenz or atazanavir) for each patient. 190 adults starting HIV treatment for the first time took part across four sites in Buenos Aires. The goal was to see if this personalized approach could reduce side effects and improve treatment success compared to standard dosing.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could show that personalized dosing based on genetics and drug levels makes HIV therapy safer and more effective.
What could go wrong: This is a small, early-stage feasibility study, not a large trial. The approach may not prove better than standard care or may be too complex for routine use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DRUG MONITORING are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DRUG MONITORING HIV PHARMACOGENETICS

Contacts and locations

Locations

Hospital Italiano de Buenos Aires - Infectious Diseases Section

Buenos Aires, Buenos Aires F.D., 1181, Argentina

More trials for these conditions

Other studies related to the condition(s) this trial covers.